| Patents for A61P 39 - General protective or antinoxious agents (19,019) |
|---|
| 06/08/2000 | CA2353795A1 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 06/07/2000 | EP0934062A4 Antioxidant activity of 3-dehydroshikimates |
| 06/07/2000 | CN1255357A Grape seed extract with strong anti-tyrosine enzyme activity and its application |
| 06/06/2000 | CA2198599C Salts of an anti-migraine indole derivative |
| 06/02/2000 | WO2000031065A1 Compounds having cytokine inhibitory activity |
| 06/02/2000 | WO2000031060A1 Scavenger compounds |
| 06/02/2000 | WO2000030425A2 Method of using pon-1 to decrease atheroma formation |
| 06/02/2000 | CA2352144A1 Scavenger compounds |
| 06/02/2000 | CA2350969A1 Compounds having cytokine inhibitory activity |
| 06/02/2000 | CA2350405A1 Method of using pon-1 to decrease atheroma formation |
| 05/31/2000 | EP1003509A1 Il-8 receptor antagonists |
| 05/31/2000 | EP1003497A1 Il-8 receptor antagonists |
| 05/30/2000 | US6069162 Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| 05/30/2000 | CA2223360C Cyclic peptide compounds and their production process |
| 05/25/2000 | WO2000029401A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/25/2000 | WO2000029371A1 Excitatory amino acid receptor modulators |
| 05/25/2000 | WO2000029025A1 Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 05/25/2000 | WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives |
| 05/25/2000 | WO2000028947A2 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 05/25/2000 | CA2350532A1 Excitatory amino acid receptor modulators |
| 05/25/2000 | CA2349919A1 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 05/25/2000 | CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/24/2000 | EP1002533A1 Use of chromanes and/or chromenes derivatives to prevent oxidative reactions induced by free radicals |
| 05/24/2000 | CN1052641C Toxin-reducing health-care liquor and its production technique |
| 05/23/2000 | US6066668 Formulations and methods of reducing toxicity of antineoplastic agents |
| 05/23/2000 | US6066645 Administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents; compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides |
| 05/18/2000 | WO2000028041A1 Delivery of superoxide dismutase to neuronal cells |
| 05/18/2000 | DE19830770C1 Wasserlösliche Zinkpyruvate bzw. deren Hydrate, Verfahren zu ihrer Herstellung und deren Verwendung Water-soluble zinc pyruvate or hydrates thereof, processes for their preparation and their use |
| 05/18/2000 | CA2349496A1 Delivery of superoxide dismutase to neuronal cells |
| 05/17/2000 | EP1000927A2 Excitatory amino acid receptor modulators |
| 05/17/2000 | EP1000087A2 Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same |
| 05/16/2000 | CA2098893C Antioxidant composition of natural products and method of production thereof |
| 05/11/2000 | WO2000026399A2 Method for the production of quercetin and isoquercetin derivatives |
| 05/11/2000 | WO2000026216A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 05/11/2000 | WO2000026206A1 Method for producing luteolin and luteolin derivatives |
| 05/11/2000 | WO2000025812A2 Method for preparing solid phase conjugate vaccines |
| 05/11/2000 | WO2000011968A8 ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID |
| 05/11/2000 | WO2000008007A3 Cyclopentabenzofuran derivatives and their use |
| 05/11/2000 | WO2000007581A3 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/11/2000 | CA2349567A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 05/11/2000 | CA2348728A1 Method for the production of quercetin and isoquercetin derivatives |
| 05/11/2000 | CA2348392A1 Method for producing luteolin and luteolin derivatives |
| 05/11/2000 | CA2348063A1 Method for preparing solid phase conjugate vaccines |
| 05/10/2000 | EP0998916A1 Medicinal compositions for application to mucosa |
| 05/10/2000 | EP0998477A1 Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents |
| 05/10/2000 | EP0736004B1 (2,4-disulfophenyl) n-tertiary butyl nitrone, its salts, and their use as pharmaceutical radical trapping agents |
| 05/09/2000 | US6060479 Quinazoline-4-one AMPA antagonists |
| 05/09/2000 | CA2112239C Enantiomeric hydroxylated xanthine compounds |
| 05/04/2000 | WO2000024922A1 Method for producing in vivo proteins chemically diversified by incorporating non-standard amino acids |
| 05/04/2000 | WO2000004868A3 Libraries of polyhydroxamates and their analogs |
| 05/04/2000 | CA2347993A1 Method for producing in vivo proteins chemically diversified by incorporating non-standard amino acids |
| 05/03/2000 | EP0996450A2 Method for the treatment of cancer with exochelins of mycobacterium tuberculosis |
| 05/03/2000 | EP0824354A4 Methods to inhibit late radiation-induced skin damage |
| 05/02/2000 | US6057361 Formulations and methods of reducing toxicity of antineoplastic agents |
| 05/02/2000 | US6056965 2-mercapto-imidazole derivatives substituted in position 4 (or 5) as antioxidizing agents, method of preparation and applications in the pharmaceutical, cosmetic or food industries |
| 05/02/2000 | CA2069961C Method and compositions for inhibition of disorders associated with oxidative damage |
| 04/27/2000 | WO2000023064A1 Treatment of dyspepsia |
| 04/27/2000 | CA2594186A1 Pharmaceutical composition containing decursin |
| 04/26/2000 | EP0994712A1 Inhibitors of neutrophil mediated oxidant production |
| 04/25/2000 | US6054261 Solution for prevention of free radical damage during perfusion of a mammalian tissue during organ transplantation; antiischemic agents |
| 04/20/2000 | WO2000021563A1 Remedies or preventives for ischemic reflow failure |
| 04/20/2000 | CA2346334A1 Composition for treating or preventing ischemia reperfusion injury |
| 04/19/2000 | EP0993433A1 Method for producing calcium pyruvates |
| 04/19/2000 | EP0993304A1 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
| 04/18/2000 | US6051587 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| 04/13/2000 | WO2000020598A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 04/13/2000 | WO2000020397A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 04/13/2000 | WO2000020390A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| 04/13/2000 | WO2000020007A1 Method and compositions for increasing bone mass |
| 04/13/2000 | CA2346537A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| 04/13/2000 | CA2346456A1 Method and compositions for increasing bone mass |
| 04/13/2000 | CA2346037A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 04/13/2000 | CA2345023A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 04/12/2000 | EP0991670A1 Method for fixing or separating ions, in particular of lead, using per(3,6-anhydro) cyclodextrin derivatives |
| 04/12/2000 | EP0991636A1 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| 04/12/2000 | CN1250375A Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents |
| 04/11/2000 | US6048873 Skin disorders |
| 04/11/2000 | US6048849 Mixture of hormone or hormone inhibitor and sulfur containing compound |
| 04/11/2000 | US6048724 Producing mammalian transfected cell strain which expresses exogenous dna encoding erythropoietin and glucagons; for prevention or treatment of a condition in which insulin production or glucagon function is defective |
| 04/11/2000 | US6048524 In vivo production and delivery of erythropoietin for gene therapy |
| 04/06/2000 | WO2000018407A1 Methods for preventing/treating damage to sensory hair cells and cochlear neurons |
| 04/05/2000 | EP0871608B1 Monofunctionalised EDTA-, DTPA- and TTHA-Derivatives and their use for the preparation of a diagnoctic or therapeutic medicine |
| 04/05/2000 | CN1051089C Fruit polyphenol, process for production thereof, and use thereof |
| 04/05/2000 | CN1051086C Heterocycle-condensed morphinoid derivs. and use thereof |
| 04/04/2000 | US6046234 Formulations and methods of reducing toxicity of antineoplastic agents |
| 04/04/2000 | US6046159 Formulations and methods of reducing toxicity of antineoplastic agents |
| 04/04/2000 | US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| 03/30/2000 | WO2000017164A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 03/29/2000 | CN1050835C 1,5-benzodiazepine derivatives and its preparation process and use in medicine |
| 03/28/2000 | US6043249 The compounds have either a sulfhydryl moiety or are reducible disulfides; antifolates |
| 03/23/2000 | WO2000015239A1 Inhibition of toxic materials or substances using dendrimers |
| 03/23/2000 | WO2000008013A3 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
| 03/23/2000 | CA2343205A1 Inhibition of toxic materials or substances using dendrimers |
| 03/22/2000 | EP0987027A1 Physiologically active extract |
| 03/21/2000 | US6040435 Antimicrobial cationic peptides |
| 03/21/2000 | US6040312 Formulations and methods of reducing toxicity of antineoplastic agents |
| 03/21/2000 | US6040304 Formulations and methods of reducing toxicity of antineoplastic agents |
| 03/21/2000 | US6040294 The compounds have either a sulfhydryl moiety or are reducible disulfides; reducing the side effect of cancer drug |
| 03/21/2000 | US6039945 Administering purified prothrombinase factor to humans |
| 03/21/2000 | CA2132745C Novel cardioprotective agents |